FDA Launches Real-Time Clinical Trials Pilot With AstraZeneca and Amgen, Aiming to End Years-Long Reporting Lags
The FDA announced two proof-of-concept real-time cancer trials and opened public comment on a broader pilot program, betting that cloud and AI-mediated data flow can compress drug review timelines.
Overview
The US Food and Drug Administration on April 28, 2026 unveiled what it described as the first concrete steps toward a long-promised overhaul of how clinical trial data reaches regulators. According to the FDA’s press release distributed via GlobeNewswire, the agency announced the successful initiation of two proof-of-concept “real-time clinical trials” (RTCTs) run by AstraZeneca and Amgen, and simultaneously opened a Request for Information (RFI) on a broader pilot program scheduled to launch this summer.
The move targets a structural feature of drug development that has gone largely unchanged for decades: trial sponsors collect, clean, and analyze data over months or years before delivering it to FDA reviewers in batches. In a real-time model, safety signals and efficacy endpoints flow to the agency through cloud-based infrastructure as they accumulate.
What Was Announced
The agency disclosed two parallel actions in the same announcement.
The first is a pair of cancer trials already running under the new model. As the FDA detailed in its press release, AstraZeneca is conducting TRAVERSE, a Phase 2 multi-site trial in patients with treatment-naïve mantle cell lymphoma, with participating sites that include The University of Texas MD Anderson Cancer Center and the University of Pennsylvania. Amgen is conducting a Phase 1b trial in limited-stage small cell lung carcinoma, with site selection still being finalized at the time of the announcement.
The second action is the RFI itself. According to the same FDA announcement, the agency will accept public comment on the proposed pilot program until May 29, 2026, plans to publish final selection criteria in July, and intends to complete pilot participant selections in August. The pilot itself is scheduled to launch over the summer.
Why It Matters
FDA Commissioner Marty Makary framed the change in stark terms. As quoted in the FDA’s press release, Makary said the agency had been conducting clinical trials “in the same way” for 60 years, with key data signals taking years to reach regulators and the resulting lag time delaying decisions. He described the new model as one in which FDA scientists can view safety signals and endpoints “in real time as a trial progresses,” with the longer-term goal of supporting “real-time, continuous trials across all phases of drug development.”
BioPharma Dive reported that AstraZeneca and Amgen will report endpoints and safety signals to FDA scientists as data accumulates rather than at traditional batched milestones, and that the agency’s stated objective is to reduce the regulatory lag time that delays decisions and ultimately to extend the model across every phase of drug development.
What We Know About the Mechanics
The technical premise is that modern clinical trial platforms, cloud storage, and machine-learning-assisted data review can shorten the gap between an event in a patient and an FDA reviewer seeing it. The FDA’s release confirmed that data signals from the AstraZeneca trial have already been received and validated by the agency, which it framed as evidence that the underlying technical framework for real-time signal sharing works.
Both proof-of-concept trials are oncology studies. Mantle cell lymphoma and small cell lung cancer are aggressive cancers with high unmet need, and they are domains where compressing the time between safety read-outs and regulatory feedback can plausibly affect patient outcomes during the trial itself, not just at approval. The FDA announcement describes the goal as helping “accelerate promising therapies” while still maintaining the agency’s review responsibilities.
What We Don’t Know
Several important questions remain open.
The FDA’s announcement does not specify how many trials will be admitted to the pilot, what categories of drugs or indications will be eligible, or how the agency will weigh applications from large pharmaceutical companies against those from smaller biotechs that may have less data infrastructure. The selection criteria are explicitly deferred to the July publication.
The announcement also does not quantify expected efficiency gains. Neither the FDA release nor BioPharma Dive’s report provides a target reduction in review time, a benchmark for what “real-time” means in practice (hours, days, or weeks), or projections for how much earlier a drug might reach approval under the new model versus the existing one.
Finally, the framework’s interaction with statistical integrity and trial blinding is not addressed in the public announcement. Real-time access to accumulating endpoint data raises questions about how interim signals will be handled without compromising trial validity — questions the pilot will presumably need to resolve through its formal selection criteria and trial-by-trial protocols.
Context
The RTCT initiative arrives during a period in which the FDA is testing several mechanisms to compress drug development timelines, including the National Priority Voucher program and the recently launched RAPID coverage pathway with CMS for breakthrough devices. Whether real-time clinical trials become a routine option or remain a narrow pilot will depend in large part on the criteria the agency releases in July and the experience of the AstraZeneca and Amgen proof-of-concept studies as they progress.
For now, the agency has set the calendar: comments on the RFI close May 29, selection criteria arrive in July, pilot participants are chosen in August, and the program launches over the summer.